Results 11 to 20 of about 51,890 (248)

Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation

Blood Cancer Journal, 2021
MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori, Rakesh Verma, Rie Nakamoto-Matsubara, Ka Tat Siu, Cristina Panaroni, Keertik S. Fulzele, Kenta Mukaihara, Chukwuamaka Onyewadume, Allison Maebius, Hiroki Kato, Lai Ping Wong, Ruslan I. Sadreyev, David T. Scadden, Noopur S. Raje   +13 more
doaj   +1 more source

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Protein & Cell, 2018
Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang, Jing Chen, Xiaoyan Han, Enfan Zhang, Xi Huang, Xing Guo, Qingxiao Chen, Wenjun Wu, Gaofeng Zheng, Donghua He, Yi Zhao, Yang Yang, Jingsong He, Zhen Cai   +13 more
doaj   +1 more source

Selinexor: Targeting a novel pathway in multiple myeloma

eJHaem, 2023
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson   +9 more
doaj   +1 more source

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]

, 2013
Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
Papa, S, Rahemtulla, A, Chaidos, A, Barbarulo, A, Karadimitris, A, Iansante, V, Naresh, K, Haskard, DO, Bubici, C, Franzoso, G   +9 more
core   +1 more source

Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase

Clinical and Applied Thrombosis/Hemostasis, 2023
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD, Adel Hajj Ali MD, Faiz Anwer MD, Raza Shahzad MD, Sandra Mazzoni DO, Louis Williams MD, Chakra Chaulagain MD, Betty Hamilton MD, Craig Sauter MD, Jack Khouri MD   +9 more
doaj   +1 more source

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

Cells, 2022
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein, E. Bridget Kim, Noopur Raje   +2 more
doaj   +1 more source

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Antibodies, 2017
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Yu-Tzu Tai   +6 more
doaj   +1 more source

Multiple Myeloma [PDF]

Clinical Journal of the American Society of Nephrology, 2006
Multiple myeloma is a malignant disease characterized by plasmacytosis, paraprotein production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the clinical features include suppression of humoral- and cell-mediated immunity, elevation of IL-6, abnormalities of the bone ...
Seema, Singhal, Jayesh, Mehta
openaire   +5 more sources

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Haematologica, 2018
Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass   +8 more
doaj   +1 more source

Second malignancies after multiple myeloma: from 1960s to 2010s. [PDF]

, 2012
To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients ...
Kristinsson, Sigurdur Y., Turesson, I, Thomas, A, Mailankody, Sham, Korde, Neha, Kristinsson, Sigurdur Y, Turesson, Ingemar, Mailankody, S, Landgren, Ola, Korde, N, Thomas, Anish, Lund University., Landgren, Carl, Turesson, Ingemar,, Kristinsson, SY, Landgren, O   +15 more
core   +1 more source